Intra-Cellular Therapies Target of Unusually Large Options Trading (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) saw some unusual options trading activity on Friday. Stock traders purchased 5,021 call options on the company. This represents an increase of 380% compared to the typical daily volume of 1,046 call options.

Intra-Cellular Therapies Price Performance

Shares of ITCI opened at $128.20 on Friday. The company has a market cap of $13.63 billion, a PE ratio of -147.35 and a beta of 0.72. The firm has a 50-day moving average of $113.68 and a 200-day moving average of $91.13. Intra-Cellular Therapies has a one year low of $63.30 and a one year high of $129.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Analysts expect that Intra-Cellular Therapies will post -0.64 earnings per share for the current year.

Insider Buying and Selling at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 51,000 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. This represents a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Intra-Cellular Therapies during the fourth quarter worth $7,951,000. GF Fund Management CO. LTD. acquired a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth about $186,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Intra-Cellular Therapies by 3.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 335,319 shares of the biopharmaceutical company’s stock worth $28,006,000 after buying an additional 12,111 shares during the period. Two Sigma Advisers LP acquired a new position in Intra-Cellular Therapies in the 4th quarter valued at about $11,966,000. Finally, Two Sigma Investments LP grew its stake in Intra-Cellular Therapies by 507.9% in the 4th quarter. Two Sigma Investments LP now owns 142,791 shares of the biopharmaceutical company’s stock valued at $11,926,000 after buying an additional 119,301 shares during the last quarter. 92.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Leerink Partnrs cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and increased their price target for the company from $119.00 to $132.00 in a research report on Friday, January 31st. StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a report on Monday, February 24th. They set a “hold” rating for the company. Finally, Mizuho lowered shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Ten research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $106.08.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.